ArticleDermatologie (Heidelberg, Germany)2025
[Ex vivo confocal laser scanning microscopy in dermatology : Techniques, indications, and perspectives].
Article in Dermatologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging In Vivo and Ex Vivo Optical Imaging Technologies in Dermatology and Dermatopathology.Dermatopathology (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ex vivo confocal laser scanning microscopy is a modern diagnostic tool that enables rapid microscopic evaluation of freshly excised skin samples without tissue loss. By combining reflectance and fluorescence imaging with digital staining algorithms, the technique produces section images that closely resemble conventional hematoxylin-eosin (HE) staining. In dermatological practice, it is primarily used for the diagnosis and margin assessment of basal cell carcinomas. The method also shows promise for squamous cell carcinomas, its precursors, and inflammatory dermatoses. Current limitations include the assessment of pigmented lesions and the differentiation of inflammatory cell infiltrates. Future developments such as artificial intelligence (AI)-assisted image analysis or fluorescence-labeled antibodies could further expand its range of applications.
Indexed as
Identifiers
40824606What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.